Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); Raising Price Target After ASCO Meeting Review

Go back to Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); Raising Price Target After ASCO Meeting Review